Summary.-The tumour used, designated MT1, is a more radiosensitive form of the anaplastic MT tumour previously described. No explanation for the increased radiosensitivity was found, but it was shown not to be due to infection or to a change in immunological status, growth rate or histology. The sensitivity has remained constant throughout the present work.
HYPoxic cells have been shown to be present in animal tumours (Thomlinson, 1960; Kallman, 1972) and are thought to be responsible for the failure, in some instances, of X-ray treatment for local control of human tumours (Fowler, 1972) .
One possible method to overcome this problem of hypoxic cells is the use of electron-affinic drugs that can mimic the radiosensitizing effect of 02, but are not so rapidly metabolized, and hence can diffuse to and radiosensitize the hypoxic cells (Adams, 1973) .
The most promising compound to date is the 2-nitroimidazole, Ro-07-0582, which has been shown to radiosensitize both bacterial and mammalian cells in vitro (Asquith et al., 1974) and tumours in situ (Sheldon and Hill, 1977) .
The present work, using local control of the MT 1 tumour, is concerned with further investigations of this compound: its cytotoxic effect if given after irradiation; its effect if given with fractionated X-rays; and the effect of varying the interval between injection and irradiation.
MATERIALS AND METHODS
The tumour investigated was the anaplastic MTI. This is a more radiosensitive form of the anaplastic MT tumour which we have previously used in radiosensitization studies (Sheldon and Hill, 1977) . The change took place in June 1975, and appeared to have occurred spontaneously, between one transplant and the next. The radiobiological response of the tumour has since remained constant.
The method used has been described in detail elsewhere (Sheldon and Hill, 1977) . Briefly, fragments of tumour were implanted s.c. over the sacral region of the backs of 8-week-old female inbred WHT/Ht mice. On reaching a mean diameter of 5 5f0-5 mm, the tumours were selected for treatment (which was always given during the morning). The dose of X-rays required to locally control 500o of the tumours (i.e. the TCD50) was determined by treating with a range of 6-8 X-ray doses, using about 12 mice per dose group.
Irradiations wAere performed without the aid of anaesthetics, by placing the mice in specially constructed lead boxes which had a portion of the lead cut away to expose the tumour to a tangential beam of 240 kV X-rays (15 mA, HVL 1-3 mm Cu, 3-62 gray/ min). To ensure uniform dose throughout the tumour mass, the mice wNere turned through 1800 halfway through the irradiation.
The mice were then observed regularly until they wNere killed at 80 days from the mid-time of treatment. At the time of killing, tumours less than 2 mm mean diameter were scored as "controlled", and more than 4 mm as "recurrent". Tumours from 2 to 4 mm would have been considered ambiguous and rejected from the analysis, but no tumours fell in this category in the present Awork. The probability of tumour control wNas computed using the logit method of maximum likelihood (Suit, Shalek and Wette, 1965) .
All mice wAere examined post mortem for the presence of macroscopic metastases. Hypoxia. This was produced by applying metal D-shaped clamps across the base of the tumour to occlude the blood supply. The clamps, were applied 10 min before commencing irradiation.
Ro-07-0582.-1-(2-hydroxy-3-methoxypropyl)-2-nitromidazole; Misonidazole, was kindly supplied by Roche Products Ltd. It was dissolved in warm isotonic saline and injected i.p. at 0-8 ml per 24-g mouse. (McNally and Sheldon, 1977) . mediately after a single dose of X-rays. The TCD50 was increased from 63 6 gray for the control mice which received X-rays only, to 68-3 gray for those receiving both X-rays and Ro-07-0582. This corresponds to a protective enhancement ratio of 0 93 (s.e. range 0 90-0.96). This observed increase in radioresistance when Ro-07-0582 was administered after irradiation was similar to that which had been observed when the tumours were clamped off to render them fully hypoxic during the irradiation (dashed line). Thus in this tumour, Ro-07-0582 appeared to have a protective rather than a cytoxic effect. The radiosensitization obtained with 0 3 mg/g Ro-07-0582 in the fractionated X-ray schedule of 5F/4d is shown in Fig. 2 . The TCD50 for the mice receiving X-rays only was 93-7 gray, and for those receiving both Ro-07-0582 and X-rays it was 63 -6 gray, giving an enhancement ratio of 1 -47 (s.e. rangbe 1*43-1.51).
The importance of the interval between injecting 0 2 mg/g Ro-07-0582 and starting to irradiate with a single dose of 50 gray of X-rays on the probability of tumour control is shown in Fig. 3 Ro-07-0582 immediately after irradiation developed metastases. In the fractionated experiment, the incidence of metastases was 8% (7/84) in the mice receiving X-rays only, and 2% (2/106) in those receiving both Ro-07-0582 and X-rays. However, according to the chi-squared test, this reduction in the incidence of metastases in the Ro-07-0582-treated mice is not significant. (P->0 08).
DISCUSSION

Tumour change
The present work is part of a larger study of hypoxic cell radiosensitization that we have carried out in vivo, but it is reported separately here because it was performed on a more radiosensitive form of the tumour, which we have designated MT I to differentiate it from the previously reported more radioresistant MT (Sheldon and Hill, 1977) . Unfortunately, such a change in a tumour's radiobiological response is not uncommon when it is investigated over a long period of time. Indeed it is a constant hazard of such studies, and has been reported previously (e.g. Peters, 1974; Fowler et al., 1975 (.1ytotoxic effects of Ro-07-0582
In vitro Ro-07-0582 has been shown to be a powerful cytotoxin specifically for hypoxic cells (Hall and Roizin-Towle, 1975; Moore, Palcic and Skarsgard, 1976; Stratford and Adams, 1977) . In vivo, a number of workers have investigated how much of the radiosensitization observed following a single injection of Ro-07-0582 given before irradiation was, in fact, due to cytotoxicity. They have done this by injecting the same quantity of drug after, instead of before, the irradiation. Their findings are summarized in Table II . In all cases, the cytotoxic enhancement ratios (ER), varying from 0 93 (present work) to 1 3, are small compared to the observed total ERs, including radiosensitization, of 1.5-2-3.
However, such in vivo experiments in mice are likely to underestimate the clinical potential of Ro-07-0582 as a specific hypoxic-cell cytotoxic agent. The in vitro cytotoxicity was only observed when hypoxic cells were exposed to a constant drug level for at least several hours. This cannot be simulated in mice after a single injection, because of the drug's short half-life of 1-I5 h (Foster, personal communication) . However, the half-life in man is 10-18 h (Foster et al., 1975) , and consequenitly the drug may be in contact with hypoxic cells in human tumours for sufficient time for it to be cytotoxic.
Effect of Ro-07-0582 with frcactionated X-rays Ro-07-0582 has been shown to be a very effective radiosensitizer in vivo with single doses of X-rays (Sheldon and Hill, 1977) . However, it is likely to be less effective with fractionated X-rays for two reasons. Firstly, reoxygenation may reduce the number of radioresistant hypoxic cells present. Secondly, both the drug and the X-ray doses per fraction would have to be less than for single doses.
This loss of effectiveness has been reported in two murine carcinomas: a C3H mammary carcinoma, which gave an ER of 1-8 for a single dose, yielded ERs of only I 1, 1 2 and 1 2 with the following fractionated schedules: 3F/4d, 5F/4d and 5F/9d (Sheldon et al., 1976) . The CBA carcinoma NT, which gave an ER of 1P7 for a single dose, yielded ERs of 1 6 and 1 2 for the two fractionation schedules 2F/2d aind 5F/9d (Denekamp and Harris, 1976) .
This loss of effectiveness is less marked in the present tumour. At the relatively low drug concentration of 0 3 mg/g, anl ER of 1 5 was obtained in the 5F/4d fractionated schedule, which is only slightly less than the 1 7 observed for a single dose of X-rays (MT tumour, Sheldon and Hill, 1977) . This small reductioin might indicate that a little reoxygenation had occurred, although by the end of the 4-day treatment the tumour had not begun to shrink, and was about 2 volume doublings larger than when treatment started. Furthermore, we had observed with the MT tumour (Sheldon and Hill, 1977) (Dische et al., 1977) .
Importance of the interval between injection and irradiation After administration of Ro-07-0582 its concentration in either serum or tumour can be measured either specifically by gas liquid chromatography or non-specifically (i.e. as 2-nitroimidazole) by polarography; such measurements have been made by Flockhart et al. (1977) . However, at present no technique exists for determining the concentration of the radiosensitizer actually in the hypoxic cells of a tumour. Therefore, the optimum time between administering the drug and starting irradiation can only be determined radiobiologically in an experiment where the interval is varied and the tumour response assayed. With the MT tumour, we had previously found that, at the relatively low drug concentration of 0.2 mg/g, an interval of 30 min resulted in a higher local control rate than an interval of 90 min (Sheldon and Hill, 1977) .
The present results show that the probability of local tumour control is significantly lower if the interval is less than 30 min or more than 75 min, with an optimum interval around 45-60 min (Fig. 3) . This finding is in accord with those of some other workers who used much higher drug concentrations. Brown (1975) found that the surviving fraction of the EMT6 tumour was lower at intervals shorter than 30 to 60 min; and Stone and Withers (1975) that the ER determined from tumour control of a mammary carcinoma was greater at 30 min than at shorter intervals.
Although the interval used is critical to the success of Ro-07-0582 as a radiosensitizer in mice, this is because of its relatively short serum half-life mentioned above. Because of the drug's longer halflife in man, the interval between administering the drug and radiotherapy may not be so critical (Dische et al., 1977) .
To conclude: we have previously described the development of the present experimental system, and the radiosensitization that was achieved by 5 different compounds when administered before a single dose of X-rays (Sheldon and Hill, 1977) . The most effective of these compounds was Ro-07-0582, which when injected i.p. 30 min before the start of irradiation, with concentrations from 041 to 1l Omg/g body weight, gave ERs from 1U5 to 241 respectively. The present paper reports (albeit on a changed form of the tumour) further investigations with this compound. It suggests that the previously reported ERs were due to hypoxic-cell radiosensitization and not, even in part, to hypoxic-cell cytotoxicity. Furthermore, even with fractionated Xray doses, a high level of radio-sensitization was observed. Finally, although an interval between injection of the drug and the start of irradiation of 30 min was used in the above work, this did not produce a significantly lower probability of local tumour control than if an optimum interval of 45-60 min had been used.
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